Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascular prevention in RA. Tofacitinib (Tofa) could possibly play a role in up-regulating levels of serum cholesterol1.But there is no evidence of CV risk management about Tofa. To examine the effect of Tofa plus methotrexate (MTX) on subclinical atherosclerosis in MTX resistant RA patients in a cohort study design.
Methods: 45 RA patients with moderate to severe active disease despite MTX treatment (disease activity score: DAS28>3.2)were received Tofa plus MTX.Arterial structures, carotid intima media thickness(CIMT) and carotid artery plaque(CAP), were measured at baseline and 54 weeks follow-up.Arterial stiffness was assessed with cardio-ankle vascular index (CAVI) and augmentation index corrected for a heart rate of 75 beats per minute (AIx@75) at baseline and 54 weeks follow-up. Clinical data were collected at regular visits. CAVI is very similar to pulse wave velocity (PWV), and CAVI measures arterial wall stiffness independent of blood pressure and it is superior to brachial ankle PWV as an index of arterial stiffness2.No new all treatments(statin, low lipids drug, and etc.) were allowed.
Results: Treatment with Tofa attenuated CIMT did not produce significant changes( 0.92±0.09mm at baseline, 0.91±0.10 mm at 54 weeks: p=0.92), CAP did not produce significant changes( 0.68±0.07 at baseline, 0.61±0.10 at 54 weeks: p=0.67)Treatment with Tofa attenuated the CAVI significantly from baseline to 54 weeks follow up(12.76 ± 1.68 and 10.22± 1.18%; p = 0.026). Treatment with Tofa attenuated the Aix@75 significantly from baseline to 54 weeks follow up(37.7 ± 5.6, 32.9 ± 5.6 %; p = 0.028). DAS 28-ESR score improved significantly from baseline to 54 weeks(5.31±1.43, 2.23±1.63: p=0.01). On the other hand, fasting serum total cholesterol TC was significantly increased from baseline to follow-up at 54 weeks (185±21.7mg/dL, 201±18.2mg/dL, p = 0.03). No patients suffered from new CV disease.
Conclusion: These findings suggest that combination therapy, Tofa with MTX not only reduced RA disease activity but also limited vascular damage despite up-regulating cholesterol in patients MTX resistant active RA. References:
1) Kremer J. et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013 Aug 20;159(4):253-61.
2) Takaki A et al. Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness. Hypertens Res.2008 Jul; 31(7):1347-55
To cite this abstract in AMA style:Kume K, Amano K, Yamada S, Kanazawa T, Hatta K, Kuwaba N. Tofacitinib Do Not Get Worse Subclinical Atherosclerosis Despite up-Regulating Serum Cholesterol in Methotrexate-Resistant Active Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tofacitinib-do-not-get-worse-subclinical-atherosclerosis-despite-up-regulating-serum-cholesterol-in-methotrexate-resistant-active-rheumatoid-arthritis-patients/. Accessed November 28, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/tofacitinib-do-not-get-worse-subclinical-atherosclerosis-despite-up-regulating-serum-cholesterol-in-methotrexate-resistant-active-rheumatoid-arthritis-patients/